Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4988)	7/24/1998 2:57:00 PM
From: margie	Read Replies (2) \| Respond to of 6136

Izzie, maybe he is trying to drum up business for Ligand. I didn't believe it until I saw these posts. To: +Andreas Helke (14538 ) From: +Henry Niman Tuesday, Feb 10 1998 11:21PM EST Reply # of 15296 Andreas, As you know, I recently posted (on AGPH board) Message 3357654 Message 3364973 Message 3377360 Message 3377373 a few (sic) reports on "Buffalo Humps" and other metabolic disease such as diabetes exacerbated or caused by PIs. In fact treating these metabolic diseases in AIDS survivors may very well represent a growing market for rexinoids. Message 3397494 To: +Andrew H (15135 ) From: +Henry Niman Sunday, Feb 15 1998 4:09PM EST Reply # of 15296 Andy, I was referring to energy metabolism. AIDS patients on PIs not only have their fat rearranged, but they also run into problems with diabetes. Energy metabolism and insulin resistance are controlled by the same general classes of receptors. The critical heteropulex for insulin resistance is PPAR gamma paired up with RXR alpha (which is activated by Targretin). For energy metabolism, its PPAR alpha, also paired up with an RXR (it may also be alpha, but the subtype is irrelevant because Targretin activates all three RXR subtypes). techstocks.com They even joke about it on the Ligand thread. One said Henry knows how to put a good spin on it. Another.... To: +Henry Niman (15118 ) From: +Andrew H Sunday, Feb 15 1998 1:43PM EST Reply # of 15296 >>Maybe AIDS patients will soon be taking Targretin to get their energy metabolism back under control:<< Henry, is this just complete speculation or a joke? Or is there some evidence that Targretin affects fat distribution? The article that he posted today is from June 16th, before the Geneva meeting started. And you know he won't quote Dr. Kotler, "The" expert on nutrition who does not point the finger at PIs as cases have been reported in patients on other drugs. And I think this is really funny: The pot calling the kettle black. Henry complaining about posters coming on the Ligand thread, and for a lot less than he is trying to do to Agouron. Message 3429708 To: +Paul Martin (15023 ) From: +Henry Niman Friday, Feb 13 1998 7:14PM EST Reply # of 15296 >Paul, I haven't been responding for some time, but of course the post still go on and on. Some of these posters claim to have no postion in LGND and/or make up positions as they go. What they do is rather obvious to the regulars, but now with all of the new posters and lurkers, it >would be nice if they just went away (but of course they cannot take a hint). Ignoring them has been tried in the past, but they can be so annoying that someone sooner or later responds and that is followed by >post after post of giberish. >Perhaps some of the newer members would like to comment to the webmistress, although I'm not sure it will do much good. Sometimes it looks like they just want to clutter up the thread so no one will read it.!!!!! Message 3434958 To: +Andrew H (15081 ) From: +Henry Niman Saturday, Feb 14 1998 5:25PM EST Reply # of 15296 Andy, I never ceases to amaze me how a poster, who is always looking for something negative to say about a company, but really has never said anything about a company's science or technology (open up his mouth to remove all doubt) can first bold comments Message 3414254 from an analysts who few have ever head of, and then when that point is made, repost the same quote, leaving off the firm's name to try to give the quote a bit more substance. <<"It always amazes me that people can get excited about rat data since it is not really predictive of how a drug will work in humans," said Americal Securities analyst Charles Engelberg.>> >I realize that not too many know who Americal Securities is, so when quoting, couldn't the poster at least give the firm a plug. I think that they could use the exposure. >So far it's LGND 4 (Bear Stearns, Robertson Stephens, Lehman Brothers, and Hambrecht & Quits), RATS 1 (Americal Securities).

To: Izzy who wrote (4988)	7/26/1998 1:20:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

Izzy, I do not understand why you (or anyone else) should waste their time on Henry, for a long time it has been clear to me that this guy has no positive interest on AGPH, he comes to this thread to push his own interests. Now about more important matters, I just received this, see if you or anyone else can check it out. ======================================================= <Three papers were just published in the Journal of Medicinal Chemistry 1998Jul16;41(15)pgs 2786-2834.I'm, sure you'll be able to get a feel of just what has been going on with the RVP project>. ======================================================= This may be very important, as it may show where is AGPH in their development of RVP. JLL